Advertisement

Bleeding pattern, outcome of accidental pregnancies and levonorgestrel plasma levels associated with method failure in NORPLANTR implants users

  • S. Díaz
    Affiliations
    Consultorio de Planificación Familiar Instituto Chileno de Medicina Reproductiva J.V. Lastarria 29, Depto. 101 Santiago, Chile

    University Hospital, Uppsala, Sweden
    Search for articles by this author
  • M. Pavez
    Affiliations
    Consultorio de Planificación Familiar Instituto Chileno de Medicina Reproductiva J.V. Lastarria 29, Depto. 101 Santiago, Chile

    University Hospital, Uppsala, Sweden
    Search for articles by this author
  • C. Herreros
    Affiliations
    Consultorio de Planificación Familiar Instituto Chileno de Medicina Reproductiva J.V. Lastarria 29, Depto. 101 Santiago, Chile

    University Hospital, Uppsala, Sweden
    Search for articles by this author
  • E.D.B. Johansson
    Affiliations
    Consultorio de Planificación Familiar Instituto Chileno de Medicina Reproductiva J.V. Lastarria 29, Depto. 101 Santiago, Chile

    University Hospital, Uppsala, Sweden
    Search for articles by this author
  • H.B. Croxatto
    Affiliations
    Consultorio de Planificación Familiar Instituto Chileno de Medicina Reproductiva J.V. Lastarria 29, Depto. 101 Santiago, Chile

    University Hospital, Uppsala, Sweden
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The aim of this study was to characterize the bleeding pattern, the outcome of pregnancies and the levonorgestrel plasma levels associated with method failures in NORPLANTR implants users. Nineteen pregnancies are reported in 458 woman and 21,589 woman-months observed during the first eight years of NORPLANTR use. Pregnancy rates increased slightly during the first six years of use,attaining a Pearl Index above three thereafter.
      All women who became pregnant had experienced a regular bleeding pattern in the six months preceding conception. Levonorgestrel plasma levels observed at different intervals before conception and during the conceptional cycle were similar to those observed in non-pregnant women at comparable intervals after NORPLANTR insertion.
      The nineteen pregnancies ended in thirteen term deliveries, one premature delivery, three abortions and two ectopic pregnancies. No abnormalities were found in the infants. The two ectopic pregnancies are the only ones reported for NORPLANTR users in The Population Council studies. The overall incidence is less than 0.8 per 1000 woman-years.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Faúndes A.
        • Sivin I.
        • Stern J.
        Long-acting contraceptive implants. An analysis of menstrual bleeding patterns.
        Contraception. 1978; 18: 355-365
        • Sivin I.
        • Alvarez Sánchez F.
        • Díaz S.
        • Holma P.
        • Coutinho E.
        • McDonald O.
        • Robertson D.N.
        • Stern J.
        Three-year experience with NORPLANT® subdermal contraception.
        Fertil. Steril. 1983; 39: 799-808
        • Díaz S.
        • Pavez M.
        • Miranda P.
        • Robertson D.N.
        • Sivin I.
        • Croxatto H.B.
        A five-year clinical trial of levonorgestrel silastic implants (Norplant®).
        Contraception. 1982; 25: 447-456
        • Sivin I.
        • Díaz S.
        • Holm P.
        • Alvarez-Sánchez F.
        • Robertson D.N.
        A four-year clinical study of NORPLANT® implants.
        Stud. Fam. Plann. 1983; 14: 184-191
        • Croxatto H.B.
        • Díaz S.
        • Miranda P.
        • Elamsson K.
        • Johansson E.D.B.
        Plasma levels of levonorgestrel in women during long-term use of Norplant®.
        Contraception. 1981; 23: 197-209
        • Sivin I.
        Findings in phase III studies of NORPLANT® implants.
        in: Zatuchni G.I. Long-Acting Contraceptive Delivery Systems. Harper Row, Philadelphia1983: 488-500
        • Díaz S.
        • Pavez M.
        • Robertson D.N.
        • Croxatto H.B.
        A three-year clinical trial with levonorgestrel silastic implants.
        Contraception. 1979; 19: 557-573
        • Weiner E.
        • Johansson E.D.B.
        Contraception with d-norgestrel silastic rods. Plasma levels of d-norgestrel and influence on the ovarian function.
        Contraception. 1976; 14: 551-562
        • Victor A.
        • Johansson E.D.B.
        Sex hormone binding globulin: The carrier protein for d-norgestrel.
        J. Clin. Endocrinol. 1976; 43: 244-247
        • Van Kammen E.
        • Thijssen J.H.H.
        • Rademaker B.
        • Schwarz F.
        The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity.
        Contraception. 1975; 12: 149-153
        • Tatum H.J.
        • Schmidt F.H.
        Contraceptive and sterilization practices and extrauterine pregnancy. A realistic perspective.
        Fertil. Steril. 1977; 28: 407-421
        • Sivin I.
        • Díaz S.
        • Holma P.
        • Alvarez-Sánchez F.
        • Robertson D.N.
        A four-year clinical study of NORPLANT® implants.
        Stud. Farn. Plann. 1983; 14: 184-191